JP2003535824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535824A5 JP2003535824A5 JP2001579836A JP2001579836A JP2003535824A5 JP 2003535824 A5 JP2003535824 A5 JP 2003535824A5 JP 2001579836 A JP2001579836 A JP 2001579836A JP 2001579836 A JP2001579836 A JP 2001579836A JP 2003535824 A5 JP2003535824 A5 JP 2003535824A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- antigen
- epitope
- item
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 description 99
- 239000000427 antigen Substances 0.000 description 49
- 108091007433 antigens Proteins 0.000 description 49
- 102000036639 antigens Human genes 0.000 description 49
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 230000002163 immunogen Effects 0.000 description 32
- 238000000034 method Methods 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 108010010995 MART-1 Antigen Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- -1 H-Ras Proteins 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 244000000056 intracellular parasite Species 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 210000005170 neoplastic cell Anatomy 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 2
- 101100118004 Arabidopsis thaliana EBP1 gene Proteins 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 101150052583 CALM1 gene Proteins 0.000 description 2
- 102100025580 Calmodulin-1 Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010072210 Cyclophilin C Proteins 0.000 description 2
- 101100459256 Cyprinus carpio myca gene Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100039717 G antigen 1 Human genes 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 2
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 2
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 2
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 description 2
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 description 2
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 description 2
- 108010030506 Integrin alpha6beta4 Proteins 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 102000016200 MART-1 Antigen Human genes 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 2
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 2
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 2
- 101150031162 TM4SF1 gene Proteins 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 102100032802 Tetraspanin-8 Human genes 0.000 description 2
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 101150091339 cam-1 gene Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 2
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56157200A | 2000-04-28 | 2000-04-28 | |
| US56157100A | 2000-04-28 | 2000-04-28 | |
| US56046500A | 2000-04-28 | 2000-04-28 | |
| US09/560,465 | 2000-04-28 | ||
| US09/561,074 | 2000-04-28 | ||
| US09/561,571 | 2000-04-28 | ||
| US09/561,572 | 2000-04-28 | ||
| US09/561,074 US6861234B1 (en) | 2000-04-28 | 2000-04-28 | Method of epitope discovery |
| PCT/US2001/013806 WO2001082963A2 (en) | 2000-04-28 | 2001-04-27 | Method of identifying and producing antigen peptides and use thereof as vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003535824A JP2003535824A (ja) | 2003-12-02 |
| JP2003535824A5 true JP2003535824A5 (enExample) | 2011-02-03 |
Family
ID=27504814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001579836A Pending JP2003535824A (ja) | 2000-04-28 | 2001-04-27 | 抗原提示細胞におけるエピトープ同調 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070269464A1 (enExample) |
| EP (4) | EP2248910A1 (enExample) |
| JP (1) | JP2003535824A (enExample) |
| CN (1) | CN1440462A (enExample) |
| AT (1) | ATE474931T1 (enExample) |
| AU (3) | AU2001257410B8 (enExample) |
| CA (1) | CA2405363A1 (enExample) |
| DE (1) | DE60142615D1 (enExample) |
| DK (1) | DK1276896T3 (enExample) |
| ES (1) | ES2347762T3 (enExample) |
| NZ (1) | NZ521715A (enExample) |
| WO (1) | WO2001082963A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US6773695B2 (en) | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
| EP1595548A3 (en) * | 2001-03-07 | 2006-02-22 | Mannkind Corporation | Anti-neovasculature preparations for treating cancer |
| WO2002069907A2 (en) * | 2001-03-07 | 2002-09-12 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| EP1752160A3 (en) | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitope sequences |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| MXPA04005382A (es) * | 2001-11-07 | 2005-02-24 | Mannkind Corp | Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno. |
| AU2008229888B2 (en) * | 2001-11-07 | 2012-07-05 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| EP1545610A4 (en) * | 2002-09-06 | 2006-11-08 | Mannkind Corp | EPITOPE SEQUENCES |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| ATE496129T1 (de) | 2003-07-22 | 2011-02-15 | Ludwig Inst Cancer Res | Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide |
| AU2005321898B2 (en) * | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| EP1838342A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| NZ587601A (en) * | 2005-06-17 | 2012-05-25 | Mannkind Corp | Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma |
| EP2385059A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| CA2643337C (en) * | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| EP2046344A2 (en) * | 2006-07-14 | 2009-04-15 | MannKind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| CA2665816C (en) | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| CN101246176B (zh) * | 2007-02-13 | 2013-06-05 | 许洋 | 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法 |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| JP5906090B2 (ja) | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ | 癌の診断のための方法およびキットならびに治療価の推定 |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| WO2012031076A1 (en) * | 2010-09-02 | 2012-03-08 | Ludwig Institute For Cancer Research, Ltd. | Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents |
| HK1199404A1 (en) * | 2011-05-26 | 2015-07-03 | Geneius Biotechnology Investments, Llc | Modulated immunodominance therapy |
| CN107817348A (zh) * | 2012-09-05 | 2018-03-20 | 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 | 发现治疗靶标的方法 |
| MX428954B (es) * | 2013-03-15 | 2025-11-13 | Univ Pennsylvania | Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana. |
| EP3524262A1 (en) * | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vectors for expression of prostate-associated antigens |
| CN104761644A (zh) * | 2014-01-03 | 2015-07-08 | 百奇生物科技（苏州）有限公司 | 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用 |
| CN103837688A (zh) * | 2014-03-27 | 2014-06-04 | 吉林农业大学 | 一种检测犬猫弓形虫抗体的间接elisa试剂盒 |
| US20170266269A1 (en) * | 2014-03-28 | 2017-09-21 | University Of Washington Through Its Center For Commercialization | Methods of identifying antigens for vaccines |
| CN113403338B (zh) | 2014-03-28 | 2025-07-15 | 华盛顿大学商业中心 | 乳腺癌和卵巢癌疫苗 |
| US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| CN104142401B (zh) * | 2014-07-25 | 2016-04-20 | 北京普恩光德生物科技开发有限公司 | 膀胱肿瘤相关抗原检测试剂盒 |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| CN105067731B (zh) * | 2015-06-05 | 2017-06-16 | 中国农业科学院兰州兽医研究所 | 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用 |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN105175498A (zh) * | 2015-10-09 | 2015-12-23 | 深圳市康尔诺生物技术有限公司 | 一种宫颈癌相关的热休克蛋白复合物及其应用 |
| WO2017096247A1 (en) | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| TWI752930B (zh) * | 2015-12-23 | 2022-01-21 | 德商梅迪基因免疫治療公司 | 抗原特異性ｔｃｒ的新生成 |
| WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| US20200182884A1 (en) * | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2018217852A1 (en) * | 2017-05-23 | 2018-11-29 | Gettysburg College | Crispr based tool for characterizing bacterial serovar diversity |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| CN112813099A (zh) * | 2019-11-15 | 2021-05-18 | 上海细胞治疗集团有限公司 | 一种在活化的t细胞中具有高活性的启动子 |
| WO2021176352A2 (en) * | 2020-03-03 | 2021-09-10 | Tarek Mohammad | Custommune: a web tool for designing personalized and population-targeted peptide vaccines |
| WO2024050547A2 (en) * | 2022-09-02 | 2024-03-07 | Hunterian Medicine Llc | Compact bidirectional promoters for gene expression |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
| US4683199A (en) * | 1983-01-31 | 1987-07-28 | Sloan-Kettering Institute For Cancer Research | Interleukin-2 dependent cytotoxic T-cell clones |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5132213A (en) * | 1986-10-02 | 1992-07-21 | Massachusetts Institute Of Technology | Method for producing proteins and polypeptides using ubiquitin fusions |
| US5093242A (en) * | 1986-10-02 | 1992-03-03 | Massachusetts Institute Of Technology | Methods of generating desired amino-terminal residues in proteins |
| US5196321A (en) * | 1986-10-02 | 1993-03-23 | Massachusetts Institute Of Technology | Methods for in vitro cleavage of ubiquitin fusion proteins |
| US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| AU611263B2 (en) * | 1988-02-12 | 1991-06-06 | Commonwealth Scientific And Industrial Research Organisation | Pox virus vectors |
| US6723832B1 (en) * | 1996-10-03 | 2004-04-20 | Ludwig Institute For Cancer Research | Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2072620C (en) | 1989-11-03 | 2007-06-12 | Donald L. Morton | Urinary tumor associated antigen, antigenic subunits uses and methods of detection |
| DE4143467C2 (de) * | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| DE4228458A1 (de) * | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5744316A (en) * | 1992-12-22 | 1998-04-28 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
| US5989565A (en) | 1993-01-29 | 1999-11-23 | University Of Pittsburgh | Elution and identification of T cell epitopes from viable cells |
| AU692152B2 (en) * | 1993-03-17 | 1998-06-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
| US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| DE4423392A1 (de) * | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Verfahren zur Identifizierung antigener Peptide |
| FR2722208B1 (fr) * | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| DE69723434T2 (de) * | 1996-04-26 | 2004-05-19 | Rijksuniversiteit Te Leiden | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope |
| US6287756B1 (en) * | 1997-05-05 | 2001-09-11 | Ludwig Institute For Cancer Research | Methods for determining presence of cancer in a sample by determining expression of an SSX gene |
| US6299295B1 (en) | 1997-07-03 | 2001-10-09 | Matsushita Electric Industrial Co., Ltd. | Ink jet printing head having ink chambers arranged in succession by lamination |
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| EP1118860A1 (en) * | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US20040236514A1 (en) * | 2001-12-13 | 2004-11-25 | Lee Stephen C. | Controlling distribution of epitopes in polypeptide sequences |
-
2001
- 2001-04-27 CN CN01812119A patent/CN1440462A/zh active Pending
- 2001-04-27 EP EP10170170A patent/EP2248910A1/en not_active Withdrawn
- 2001-04-27 AU AU2001257410A patent/AU2001257410B8/en not_active Ceased
- 2001-04-27 DK DK01930922.8T patent/DK1276896T3/da active
- 2001-04-27 EP EP10178766A patent/EP2278024A1/en not_active Withdrawn
- 2001-04-27 CA CA002405363A patent/CA2405363A1/en not_active Abandoned
- 2001-04-27 AT AT01930922T patent/ATE474931T1/de not_active IP Right Cessation
- 2001-04-27 DE DE60142615T patent/DE60142615D1/de not_active Expired - Lifetime
- 2001-04-27 WO PCT/US2001/013806 patent/WO2001082963A2/en not_active Ceased
- 2001-04-27 AU AU5741001A patent/AU5741001A/xx active Pending
- 2001-04-27 JP JP2001579836A patent/JP2003535824A/ja active Pending
- 2001-04-27 ES ES01930922T patent/ES2347762T3/es not_active Expired - Lifetime
- 2001-04-27 EP EP10178756A patent/EP2278023A1/en not_active Withdrawn
- 2001-04-27 NZ NZ521715A patent/NZ521715A/en not_active IP Right Cessation
- 2001-04-27 EP EP01930922A patent/EP1276896B1/en not_active Expired - Lifetime
-
2007
- 2007-03-07 US US11/683,397 patent/US20070269464A1/en not_active Abandoned
-
2010
- 2010-12-14 AU AU2010251790A patent/AU2010251790B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice | |
| AU2001257410B8 (en) | Method of identifying and producing antigen peptides and use thereof as vaccines | |
| JP2012500652A5 (enExample) | ||
| JP2021035366A5 (enExample) | ||
| Gupta et al. | A two-component DNA-prime/protein-boost vaccination strategy for eliciting long-term, protective T cell immunity against Trypanosoma cruzi | |
| JP2010533649A5 (enExample) | ||
| Zamudio-Ortega et al. | Morphological, chemical and structural characterisation of deciduous enamel: SEM, EDS, XRD, FTIR and XPS analysis. | |
| JP2011041578A5 (enExample) | ||
| Korsholm et al. | Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status | |
| AU2001257410A1 (en) | Method of identifying and producing antigen peptides and use thereof as vaccines | |
| Mehravaran et al. | Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice | |
| Karbach et al. | Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies | |
| Kumar et al. | Immunoinformatics-based multi-epitope containing fused polypeptide vaccine design against visceral leishmaniasis with high immunogenicity and TLR binding | |
| Herrmann et al. | The STEAP1262–270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA‐A* 0201 transgenic mice—A new approach to immunotherapy against prostate carcinoma | |
| Aebischer | Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis | |
| Iurescia et al. | Strategies for improving DNA vaccine performance | |
| Kastner et al. | Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel M ycobacterium tuberculosis fusion protein: a multivariate analysis study | |
| Giannouli et al. | Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. | |
| dos Santos et al. | A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection | |
| WO2003057823A2 (en) | Epitope synchronization in antigen presenting cells | |
| An et al. | The multivalent minigene approach to vaccine development | |
| Cohen et al. | Immunoinformatics: the next step in vaccine design | |
| Harada et al. | P56. A novel cancer vaccine with nanogel-based antigen transporter and sequence-optimised long peptide antigen | |
| Eickhoff et al. | Generation of novel Chagas vaccines: evolving studies/work in progress | |
| Mueller et al. | Abstract A170: The mode of action of Orf virus–a novel viral vector for therapeutic cancer vaccines |